$876.00+9.13% · 3M
Moving avg
1W+0.93%
1M-0.03%
3M+9.13%
6M+4.97%
YTD+4.29%
1Y+37.40%
3Y+72.79%
5Y+181.98%
52-week range
$631.4776% of range$953.58
Company health
Value0/6
Growth6/6
Profitability6/6
Health6/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 24% upside to a $1090 target
- Analyst consensus is "Buy"
- Strong 31% net margin
- High return on equity (2166%)
- Revenue compounding 86% a year
- Net cash on the balance sheet
Risks
No obvious red flags from the metrics.
Key statistics
Valuation
Market cap
$54.48B
Enterprise value
$48.55B
P/E ratio (TTM)
30.36x
P/S ratio (TTM)
10.04x
EV/EBITDA
30.57x
Per share & returns
EPS (TTM)
$27.41
Dividend yield
0.00%
Beta (1Y)
-0.02
30-day change
-0.03%
Trading
Volume (24h)
172.31K
Previous close
$864.74
Shares outstanding
62.19M
About argenx SE
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
ARGX
argenx SE is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (Netherlands) and trade under the ticker ARGX.
Frequently asked questions
What is argenx SE's market cap?
argenx SE (ARGX) has a market capitalization of $54.48B.
What is argenx SE's P/E ratio?
argenx SE trades at a price-to-earnings (P/E) ratio of 30.36.
What exchange does ARGX trade on?
ARGX trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,220.51+0.45%
$1.15T cap
Johnson & JohnsonJNJ
$260.86+0.41%
$628.65B cap
AbbVie Inc.ABBV
$248.66-0.57%
$439.33B cap
UnitedHealth Group IncorporatedUNH
$405.59+0.85%
$368.33B cap
Roche Holding AGSWX: ROP
CHF 363.20-0.63%
$355.68B cap
Merck & Co., Inc.MRK
$132.93+1.92%
$328.31B cap
Novartis AGSWX: NOVN
CHF 123.68-0.42%
$289.21B cap
AstraZeneca PLCLON: AZN
£116.54-0.41%
$243.66B cap